Mechanism of action of methylphenidate: Insights from PET imaging studies
Abstract
Methylphenidate (MPH) is the most commonly prescribed drug for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). We have used Positron Emission Tomography (PET) to investigate the mechanism of action of MPH in the human brain. We have shown (a) that oral MPH reaches peak concentration in the brain 60–90 minutes after its administration, (b) that therapeutic doses of MPH block more than 50% of the dopamine transporters (DAT), and (c) that of the two enantiomers that compose MPH, it is d-threo-methylphenidate (d-MPH) and not l-threo-methylphenidate (l-MPH) that binds to the DAT. We have also shown that therapeutic doses of MPH significantly enhance extracellular dopamine (DA) in the basal ganglia, which is an effect that appears to be modulated by the rate of DA release and that is affected by age (older subjects show less effect). Thus, we postulate (a) that MPH's therapeutic effects are in part due to amplification of DA signals, (b) that variability in responses is in part due to differences in DA tone between subjects, and (c) that MPH's effects are context dependent. Because DA enhances task specific neuronal signaling and decreases noise, we also postulate that MPH-induced increases In DA could improve attention and decrease distractibility; and that since DA modulates motivation, the increases in DA would also enhance the saliency of the task facilitating the “interest it elicits” and thus improving performance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MPH is a NE-DA reuptake inhibitor; therefore, it causes an increase of catecholamines in the synaptic cleft (shown by PET imaging).
“MPH is a NE–DA reuptake inhibitor; therefore, it causes an increase of catecholamines in the synaptic cleft [shown by positron emission tomography (PET) imaging] [131].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [131]
Both drugs promote the activation of DRD1, DRD5, ADRA2A and ADRA2B, modulating dopaminergic and adrenergic signalling, thereby regulating reuptake and release of catecholamines (primarily NE and DA) on the synaptic cleft.
“Regarding the indirect drug-induced molecular changes, both drugs promote the activation of DRD1, DRD5, ADRA2A and ADRA2B, then modulate the dopaminergic and adrenergic signalling, therefore regulating the reuptake and release of catecholamines (primarily NE and DA) on the synaptic cleft [131, 153].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [131]
The therapeutic dose of MPH works primarily via increasing DA signaling through DAT blockade in the PFC and enhancing extracellular DA release in the striatum, and indirectly increasing NE actions through blockade of its transporters.
“The therapeutic dose of MPH works primarily via (1) increasing DA signaling through multiple actions, including DAT blockade in the PFC, and significantly enhancing extracellular DA release in the striatum (Volkow et al., 2002; Wilens, 2008) and (2) indirectly increasing NE actions through blockade of its transporters (Berridge et al., 2006).”
From The Effects of Methylphenidate on Goal-directed Behavior in a Rat Model of ADHD (2015) · cites this paper as Volkow et al., 2002
Cites
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127 · see citing works
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · see citing works
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623 · see citing works
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · see citing works
Self-citationVolkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321 · see citing works
Self-citationDing, Y.-S., Fowler, J. S., Volkow, N. D., Dewey, S. L., Wang, G.-J., Logan, J., Gatley, S. J., & Pappas, N. (1997) · Psychopharmacology · doi:10.1007/s002130050267 · Cited by 157 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
ADHD Working Group of the Psychiatric Genomics Consortium (PGC), Demontis, D., Early Lifecourse & Genetic Epidemiology (EAGLE) Consortium, 23andMe Research Team, Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., Baldursson, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0269-7 · Cited by 2,203 · see citing works
Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.01.006 · Cited by 875 · see citing works
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685 · see citing works
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631 · see citing works
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · see citing works
Tripp, G., & Wickens, J. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.026 · Cited by 492 · see citing works
The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Madras, B. K., Miller, G. M., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.011 · Cited by 393 · see citing works
Attention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358 · see citing works
Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.016 · Cited by 315 · see citing works
Cingulate, Frontal, and Parietal Cortical Dysfunction in Attention-Deficit/Hyperactivity Disorder
Bush, G. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.022 · Cited by 304 · see citing works
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269 · see citing works
Beyond polemics: science and ethics of ADHD
Singh, I. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2514 · Cited by 233 · see citing works
PIETRZAK, R., MOLLICA, C., MARUFF, P., & SNYDER, P. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.10.002 · Cited by 214 · see citing works
Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder.
Sikström, S., & Söderlund, G. (2007) · Psychological Review · doi:10.1037/0033-295x.114.4.1047 · Cited by 205 · see citing works
Bush, G., Spencer, T. J., Holmes, J., Shin, L. M., Valera, E. M., Seidman, L. J., Makris, N., Surman, C., Aleardi, M., Mick, E., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.16 · Cited by 201 · see citing works
Rubia, K., Halari, R., Cubillo, A., Smith, A. B., Mohammad, A.-M., Brammer, M., & Taylor, E. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.30 · Cited by 184 · see citing works
Rubia, K., Halari, R., Mohammad, A.-M., Taylor, E., & Brammer, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.018 · Cited by 171 · see citing works
Hodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0286-5 · Cited by 147 · see citing works
The effects of methylphenidate on decision making in attention-deficit/hyperactivity disorder
DeVito, E. E., Blackwell, A. D., Kent, L., Ersche, K. D., Clark, L., Salmond, C. H., Dezsery, A. M., & Sahakian, B. J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.017 · Cited by 142 · see citing works
Zhu, J., & Reith, M. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927877 · Cited by 140 · see citing works
Gatzke-Kopp, L. M., Beauchaine, T. P., Shannon, K. E., Chipman, J., Fleming, A. P., Crowell, S. E., Liang, O., Johnson, L. C., & Aylward, E. (2009) · Journal of Abnormal Psychology · doi:10.1037/a0014378 · Cited by 137 · see citing works
Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release
Oswald, L. M., Wong, D. F., Zhou, Y., Kumar, A., Brasic, J., Alexander, M., Ye, W., Kuwabara, H., Hilton, J., & Wand, G. S. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.01.055 · Cited by 108 · see citing works
Agay, N., Yechiam, E., Carmel, Z., & Levkovitz, Y. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1853-4 · Cited by 101 · see citing works
Bralten, J., Franke, B., Waldman, I., Rommelse, N., Hartman, C., Asherson, P., Banaschewski, T., Ebstein, R. P., Gill, M., Miranda, A., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.08.020 · Cited by 93 · see citing works
Stoy, M., Schlagenhauf, F., Schlochtermeier, L., Wrase, J., Knutson, B., Lehmkuhl, U., Huss, M., Heinz, A., & Ströhle, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2166-y · Cited by 91 · see citing works
Early development of subcortical regions involved in non-cued attention switching
Casey, B. J., Davidson, M. C., Hara, Y., Thomas, K. M., Martinez, A., Galvan, A., Halperin, J. M., Rodríguez‐Aranda, C. E., & Tottenham, N. (2004) · Developmental Science · doi:10.1111/j.1467-7687.2004.00377.x · Cited by 80 · see citing works
Quintero, J., Gutiérrez-Casares, J. R., & Álamo, C. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00392-2 · Cited by 70 · see citing works
“Amine oxidase [flavin-containing] B MAOB ; [131, 133]”
BackgroundInfluentialBalcioglu, A., Ren, J.-Q., McCarthy, D., Spencer, T. J., Biederman, J., & Bhide, P. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.025 · Cited by 60 · see citing works
Pozzi, M., Carnovale, C., Peeters, G. G. A. M., Gentili, M., Antoniazzi, S., Radice, S., Clementi, E., & Nobile, M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.021 · Cited by 56 · see citing works
Jezierski, G., Zehle, S., Bock, J., Braun, K., & Gruss, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04927.x · Cited by 41 · see citing works
Yeh, C.-B., Lee, C.-S., Ma, K.-H., Lee, M.-S., Chang, C.-J., & Huang, W.-S. (2007) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2007.01.003 · Cited by 41 · see citing works
Are Motivation Deficits Underestimated in Patients With ADHD? A Review of the Literature
Modesto-Lowe, V., Chaplin, M., Soovajian, V., & Meyer, A. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2677 · Cited by 41 · see citing works
Nikolaus, S., Wirrwar, A., Antke, C., Arkian, S., Schramm, N., M�ller, H.-W., & Larisch, R. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1615-9 · Cited by 29 · see citing works
Effects of methylphenidate: the cellular point of view
Bartl, J., Link, P., Schlosser, C., Gerlach, M., Schmitt, A., Walitza, S., Riederer, P., & Grünblatt, E. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0039-6 · Cited by 29 · see citing works
The Effects of Methylphenidate on Goal-directed Behavior in a Rat Model of ADHD
Natsheh, J. Y., & Shiflett, M. W. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00326 · Cited by 21 · see citing works
Colzato, L. S., & Arntz, F. E. (2017) · Theory-Driven Approaches to Cognitive Enhancement · doi:10.1007/978-3-319-57505-6_6 · Cited by 2 · see citing works
- Authors
- Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y., & Gatley, S. J.
- Affiliations
- State University of New York (US)
- Brookhaven National Laboratory (US)
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2002-04
- Volume
- 6
- Issue
- 1_suppl
- Pages
- 31-43
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2405138604
- Cited by
- 353
- References
- 6
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 20 · 2020: 14 · 2019: 19 · 2018: 21 · 2017: 16 · 2016: 20 · 2015: 11 · 2014: 21 · 2013: 30 · 2012: 14
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01da009490-08)
- National Institute on Drug Abuse (DA 09490-01, DA-06278, R01DA006278)
- Brookhaven National Laboratory
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, dopamine transporter, enantiomers, extracellular dopamine, basal ganglia, dopamine release, age differences, mechanism of action, brain drug concentration, attention, motivation
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Basal Ganglia, Brain, Brain Mapping, Child, Dopamine, Humans, Membrane Glycoproteins, Methylphenidate, Middle Aged, Nerve Tissue Proteins, Stereoisomerism, Tomography, Emission-Computed, Treatment Outcome, Membrane Transport Proteins, Membrane Transport Modulators, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
